Research
We are contributing to the fight to eradicate cancer
We are using targeted lipid nanoparticles, TLNs, to selectively bring chemotherapy only to cancer and avoid healthy tissues. TLNs eradicate cancer with minimal adverse-effects. Our goal is to extend and enhance the quality of life of cancer patients.
Delivering the Chemotherapy Only to Tumor
DoricPharma has a patented drug delivery platform, Targeted Lipid Nanoparticles, TLNs. TLNs deliver chemotherapeutics selectively only to tumors, thereby sparing the healthy organs from the adverse-effects of the chemotherapy. TLNs maintain prolonged concentrations of chemotherapeutics in tumors while improving their therapeutic efficacy and reducing their adverse effects.
TLNs in Pancreatic Cancer
The TLNs drug delivery technology has been shown to target pancreatic tumors in mice, deliver the drug over an extended period of time, and significantly reduce or obliterate orthotopic or subcutaneous orthotopic tumors in mice.
Intellectual Property
Doric Pharma's TLNs technology is supported by US and international patents
Country and Patent Number
​
USA US9808425
Canada 2,846,670
Europe 12830510
​
​
​
​
Country and Patent Number
Japan 6258202
China 202180043744.0
Israel 230,987
​
We thank NIH/NCI for their support:
R41CA247009-01, PI: Lambros, M., $299,559
R41CA247009-01S1, PI: Lambros, M., $102,195
R41CA247009-01S2, PI: Lambros, M., $52,000
​
​
The Team
Mike Nicolaou, PhD
CEO and Manager of Operations
Dr Nicolaou is a Pharmaceutical Chemist with 23 years of industrial experience in pharmaceutical industry. He has worked in the areas of product development, manufacturing and quality control and contributed to four new commercial pharmaceutical products in the areas of diabetes and metabolic diseases, and a vaccine product currently in clinical trials in the area of oncology.
